[Adjuvant chemotherapy in cancers of the stomach, pancreas and intestine].
Adjuvant chemotherapy after apparently complete resection of gastrointestinal cancer may be theoretically justified by the high rate of local and metastatic recurrences. However, the results of controlled trials are generally disappointing, even if some of them have recently suggested some hope, chiefly for adjuvant therapy in gastric cancer. Confirmation of these preliminary results is needed before considering adjuvant therapy as routine treatment in digestive tumors.
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003110:Colonic Neoplasms / Q000188:drug therapy; D003131:Combined Modality Therapy; D004351:Drug Resistance; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D007414:Intestinal Neoplasms / Q000188:drug therapy* / Q000601:surgery; D010190:Pancreatic Neoplasms / Q000188:drug therapy*; D011379:Prognosis; D012004:Rectal Neoplasms / Q000188:drug therapy; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000601:surgery
D000970:Antineoplastic Agents; D005472:Fluorouracil
La chimiothérapie adjuvante dans les cancers de l'estomac, du pancréas et de l'intestin.